PT  - JOURNAL ARTICLE
AU  - W. David Jarvis
AU  - Frank A. Fornari, Jr.
AU  - Robert M. Tombes
AU  - Ravi K. Erukulla
AU  - Robert Bittman
AU  - Gary K. Schwartz
AU  - Paul Dent
AU  - Steven Grant
TI  - Evidence for Involvement of Mitogen-Activated Protein Kinase, Rather than Stress-Activated Protein Kinase, in Potentiation of 1-β-<span class="sc">d</span>-Arabinofuranosylcytosine-Induced Apoptosis by Interruption of Protein Kinase C Signaling
AID  - 10.1124/mol.54.5.844
DP  - 1998 Nov 01
TA  - Molecular Pharmacology
PG  - 844--856
VI  - 54
IP  - 5
4099  - http://molpharm.aspetjournals.org/content/54/5/844.short
4100  - http://molpharm.aspetjournals.org/content/54/5/844.full
SO  - Mol Pharmacol1998 Nov 01; 54
AB  - The stress-activated protein kinase (SAPK) and mitogen-activated protein kinase (MAPK) cascades mediate cytotoxic and cytoprotective functions, respectively, in the regulation of leukemic cell survival. Involvement of these signaling systems in the cytotoxicity of 1-β-d-arabinofuranosylcytosine (ara-C) and modulation of ara-C lethality by protein kinase C PKC inhibition/down-regulation was examined in HL-60 promyelocytic leukemia cells. Exposure to ara-C (10 μm) for 6 hr promoted extensive apoptotic DNA damage and cell death, as well as activation of PKC. This response was accompanied by downstream activation of the SAPK and MAPK cascades. PKC-dependent MAPK activity seemed to limit ara-C action in that the toxicity of ara-C was enhanced by pharmacological reductions of PKC, MAPK, or both. Thus, ara-C action was (1) partially attenuated by diradylglycerols, which stimulated PKC and MAPK, but (2) dramatically amplified by sphingoid bases, which inhibited PKC and MAPK. The cytotoxicity of ara-C also was substantially increased by pharmacological reductions of PKC, including down-regulation of PKC by chronic preexposure to the macrocyclic lactone bryostatin 1 or inhibition of PKC by acute coexposure to the dihydrosphingosine analog safingol. Significantly, both of these manipulations prevented activation of MAPK by ara-C. Moreover, acute disruption of the MAPK module by AMF, a selective inhibitor of MEK1, suppressed both basal and drug-stimulated MAPK activity and sharply increased the cytotoxicity of ara-C, suggesting the direct involvement of MAPK as a downstream antiapoptotic effector for PKC. None of these chemopotentiating agents enhanced ara-CTP formation. Ceramide-driven SAPK activity did not seem to mediate drug-induced apoptosis, given that (1) neutralization of endogenous tumor necrosis factor-α with monoclonal antibodies or soluble tumor necrosis factor receptor substantially reduced ceramide generation and SAPK activation by ara-C, whereas the induction of apoptosis was unaffected; (2) pharmacological inhibition of sphingomyelinase by 3-O-methoxysphingomyelin reduced ceramide generation and SAPK activation without limiting the drug’s cytotoxicity; and (3) potentiation of ara-C action by bryostatin 1 or safingol was not associated with further stimulation of SAPK. These observations collectively suggest a primary role for decreased MAPK, rather than increased SAPK, in the potentiation of ara-C cytotoxicity by interference with PKC-dependent signaling.